Windward Bio seeks $1 billion valuation with Novo's backing in US IPO

Windward Bio is pursuing a US initial public offering with its sights set on a $1 billion valuation, a level that would place the drug developer among the more closely watched biotech debuts of the year. The company arrives with backing from Novo, a connection likely to draw attention from investors weighing early-stage science.

The move comes as the market for new biotech listings has turned uneven. Higher financing costs and risk aversion kept many young drugmakers private for a stretch, and issuance has only recently picked up, with buyers remaining selective. Companies offering clear scientific stories and well-funded sponsors have found receptions; others have postponed or scaled back.

For Windward, the Novo link is likely to be central to the pitch. Large life sciences backers can offer more than capital: development expertise, manufacturing relationships and potentially a future partner for the company's programs. Investors often read such support as validation of the underlying science.

Much depends on pricing and demand when the deal launches. Reaching $1 billion would signal that appetite for well-sponsored biotech is intact; falling short would underscore how selective the market remains. Either outcome will be read as a gauge for the queue of issuers waiting behind it.